For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
Agenda
Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for chronic lymphocytic leukemia (CLL). Each event will employ an identical format that will include the following elements:
Module 1: Optimal Integration of Venetoclax and BTK Inhibitors into the Front-Line Setting
Module 2: Management of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Target Audience
These activities are intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL).
Learning Objectives
CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.
FACULTY — Dr Wierda has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Dr Abramson — Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Novartis; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc. Dr Allan — Advisory Committee: AbbVie Inc, Ascentage Pharma, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc. Dr Coutre — Advisory Committee: AbbVie Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Syros Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, BeiGene Ltd. Dr Davids — Advisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. Dr Flinn — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Gilead Sciences Inc, Great Point Partners LLC, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, ScienceCurio, Seagen Inc, Takeda Oncology, Unum Therapeutics, Verastem Inc, Vincere Biosciences Inc, YL-Pharma Co Ltd; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, F Hoffmann-La Roche Ltd, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Roche Laboratories Inc, Seagen Inc, Takeda Oncology, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research & Development Corp, Unum Therapeutics, Verastem Inc. Prof Gribben — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, MorphoSys, Novartis; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Hill — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Novartis; Contracted Research: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Takeda Oncology. Dr Jain — Advisory Committee and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Precision BioSciences, Servier, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics SA, Aprea Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cellectis, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Precision BioSciences, Servier; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc. Dr Kahl — Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation. Dr Mato — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Octapharma, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Celgene Corporation, TG Therapeutics Inc. Dr Pagel — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Gilead Sciences Inc, Takeda Oncology. Dr Rogers — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Travel: AstraZeneca Pharmaceuticals LP. Dr Sharman — Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc. Dr Siddiqi — Advisory Committee: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: BeiGene Ltd; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr Smith — Advisory Committee: AbbVie Inc, Janssen Biotech Inc; Contracted Research: Karyopharm Therapeutics; Speaker's Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma, Kite, A Gilead Company. Dr Thompson — Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, VelosBio Inc; Other: CME talks sponsored by Janssen Biotech Inc. Dr Woyach — Advisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.